SRPT – Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

SRPT

$15.91

Name : Sarepta Therapeutics, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $1,563,587,072.00

EPSttm : -2.64

Sarepta Therapeutics, Inc.

$15.91

3.11%

$0.51

Float Short %

15.89

Margin Of Safety %

Put/Call OI Ratio

0.66

EPS Next Q Diff

4.68

EPS Last/This Y

-4.54

EPS This/Next Y

5.5

Price

15.91

Target Price

28.42

Analyst Recom

2.86

Performance Q

-74.66

Relative Volume

0.86

Beta

0.45

Ticker: SRPT

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-04	SRPT	18.2	0.46	0.34	179797
2025-07-07	SRPT	17.34	0.46	0.90	174836
2025-07-08	SRPT	19.03	0.47	0.19	176796
2025-07-09	SRPT	19.36	0.47	0.38	181624
2025-07-10	SRPT	19.06	0.46	0.56	182681
2025-07-11	SRPT	18.17	0.47	0.39	183063
2025-07-14	SRPT	19.23	0.47	0.25	177715
2025-07-15	SRPT	18.22	0.47	0.29	180101
2025-07-16	SRPT	18.5	0.47	1.87	182090
2025-07-17	SRPT	22	0.48	0.50	185605
2025-07-18	SRPT	14.06	0.50	1.64	197740
2025-07-21	SRPT	13.29	0.64	1.71	216502
2025-07-22	SRPT	13.62	0.72	1.17	245242
2025-07-23	SRPT	13.3	0.76	0.66	268159
2025-07-24	SRPT	12.91	0.74	0.97	273489
2025-07-25	SRPT	11.91	0.74	1.11	299866
2025-07-28	SRPT	13.85	0.72	0.57	271473
2025-07-29	SRPT	15.85	0.72	0.78	289647
2025-07-30	SRPT	16.73	0.68	0.28	306628
2025-07-31	SRPT	16.44	0.67	0.37	320874
2025-08-01	SRPT	15.89	0.66	0.48	324750
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-04	SRPT	18.24	165.2	250.4	-1.89
2025-07-07	SRPT	17.34	165.2	246.7	-1.89
2025-07-08	SRPT	19.03	165.2	257.2	-1.89
2025-07-09	SRPT	19.37	165.2	251.5	-1.89
2025-07-10	SRPT	19.07	165.2	249.1	-1.89
2025-07-11	SRPT	18.17	165.2	245.7	-1.89
2025-07-14	SRPT	19.23	165.2	254.4	-1.89
2025-07-15	SRPT	18.21	165.2	246.3	-1.89
2025-07-16	SRPT	18.39	165.2	250.9	-1.89
2025-07-17	SRPT	21.97	165.2	264.3	-1.89
2025-07-18	SRPT	14.08	165.2	223.0	-1.89
2025-07-21	SRPT	13.30	165.2	-143.3	-1.89
2025-07-22	SRPT	13.61	165.2	-157.7	-1.89
2025-07-23	SRPT	13.32	153.5	-254.3	-1.89
2025-07-24	SRPT	12.88	153.5	-251.5	-1.89
2025-07-25	SRPT	11.93	153.5	-241.4	-2.82
2025-07-28	SRPT	13.95	153.5	-300.1	-2.82
2025-07-29	SRPT	15.83	153.5	-295.6	-2.96
2025-07-30	SRPT	16.75	164.0	-275.5	-2.96
2025-07-31	SRPT	16.42	164.0	-254.4	-2.96
2025-08-01	SRPT	15.91	164.0	-251.3	-2.20
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-04	SRPT	-0.05	-0.98	10.58
2025-07-07	SRPT	-0.05	-0.98	10.58
2025-07-08	SRPT	-0.05	-0.98	10.58
2025-07-09	SRPT	-0.05	-0.98	10.58
2025-07-10	SRPT	-0.05	-0.98	10.58
2025-07-11	SRPT	-0.05	-0.98	15.71
2025-07-14	SRPT	-0.05	-0.90	15.71
2025-07-15	SRPT	-0.05	-0.90	15.71
2025-07-16	SRPT	-0.05	-0.90	15.71
2025-07-17	SRPT	-0.05	-0.90	15.71
2025-07-18	SRPT	-0.05	-0.90	15.71
2025-07-21	SRPT	-0.05	-1.76	15.71
2025-07-22	SRPT	-0.05	-1.76	15.71
2025-07-23	SRPT	-0.05	-1.76	15.71
2025-07-24	SRPT	-0.05	-1.76	15.71
2025-07-25	SRPT	-0.05	-1.76	15.89
2025-07-28	SRPT	-0.05	-1.75	15.89
2025-07-29	SRPT	-0.05	-1.75	15.89
2025-07-30	SRPT	-0.05	-1.75	15.89
2025-07-31	SRPT	-0.05	-1.75	15.89
2025-08-01	SRPT	-0.05	-1.75	15.89
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-4.6

Avg. EPS Est. Current Quarter

1.17

Avg. EPS Est. Next Quarter

0.08

Insider Transactions

-0.05

Institutional Transactions

-1.75

Beta

0.45

Average Sales Estimate Current Quarter

530

Average Sales Estimate Next Quarter

343

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

91.3

Max Drawdown 5-Year %

-93.3

Target Price

28.42

P/E

Forward P/E

7.43

PEG

P/S

0.7

P/B

1.37

P/Free Cash Flow

EPS

-2.58

Average EPS Est. Cur. Y

-2.2

EPS Next Y. (Est.)

3.3

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-11.12

Relative Volume

0.86

Return on Equity vs Sector %

-45.5

Return on Equity vs Industry %

-26.8

EPS 1 7Days Diff

0.6

EPS 1 30Days Diff

-0.31

EBIT Estimation

-251.3

Sarepta Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 1372

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

stock quote shares SRPT – Sarepta Therapeutics, Inc. Stock Price stock today

news today SRPT – Sarepta Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch SRPT – Sarepta Therapeutics, Inc. yahoo finance google finance

stock history SRPT – Sarepta Therapeutics, Inc. invest stock market

stock prices SRPT premarket after hours

ticker SRPT fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

SRPT – Sarepta Therapeutics, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: SRPT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y